Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
GEMINI II
A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
8 other identifiers
interventional
1,116
3 countries
114
Brief Summary
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Dec 2008
Typical duration for phase_3
114 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 31, 2008
CompletedFirst Posted
Study publicly available on registry
November 3, 2008
CompletedStudy Start
First participant enrolled
December 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2012
CompletedResults Posted
Study results publicly available
July 21, 2014
CompletedJuly 21, 2014
June 1, 2014
3.2 years
October 31, 2008
June 19, 2014
June 19, 2014
Conditions
Outcome Measures
Primary Outcomes (3)
Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
Week 6
Induction Phase: Percentage of Participants With Enhanced Clinical Response at Week 6
Enhanced clinical response is defined as a CDAI score at least 100 points lower than Baseline. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.
Baseline and Week 6
Maintenance Phase: Percentage of Participants Achieving Clinical Remission at Week 52
Clinical remission is defined as a CDAI score ≤ 150. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
Week 52
Secondary Outcomes (4)
Induction Phase: Change From Baseline in C-Reactive Protein (CRP) Levels at Week 6
Baseline and Week 6
Maintenance Phase: Percentage of Participants With Enhanced Clinical Response at Week 52
Baseline and Week 52
Maintenance Phase: Percentage of Participants in Corticosteroid-free Clinical Remission at Week 52
Week 52
Maintenance Phase: Percentage of Participants With Durable Clinical Remission
Assessed every 4 weeks from Week 6 to Week 50, and at Week 52
Study Arms (2)
Vedolizumab
EXPERIMENTALIn the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15). In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase.
Placebo
PLACEBO COMPARATORIn the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
Interventions
Vedolizumab for intravenous infusion
Eligibility Criteria
You may qualify if:
- Age 18 to 80
- Diagnosis of moderately to severely active Crohn's disease (CD)
- CD involvement of the ileum and/or colon
- Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents, within protocol-specified parameters:
- Immunomodulators
- Tumor necrosis factor-alpha (TNFα) antagonists
- Corticosteroids
- May be receiving a therapeutic dose of conventional therapies for irritable bowel disease (IBD) defined by the protocol
You may not qualify if:
- Evidence of abdominal abscess at the initial screening visit, other than a minimum of 10 aphthous ulcerations involving a minimum of 10 contiguous cm of intestine
- Extensive colonic resection, subtotal or total colectomy
- History of \>3 small bowel resections or diagnosis of short bowel syndrome
- Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
- Have received non permitted IBD therapies within either 30 or 60 days, depending on the medication, as stated in the protocol
- Chronic hepatitis B or C infection
- Active or latent tuberculosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (114)
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
Apex Clinical Trials
Birmingham, Alabama, 35234, United States
Gastrointestinal Bioscience
Los Angeles, California, 90067, United States
Paramount Medical Specialty
Montebello, California, 90640, United States
Capital Gastroenterology Consultants Medical Group
Sacramento, California, 95815, United States
Clinical Applications Laboratories Inc.
San Diego, California, 92103, United States
Desta Digestive Disease Medical Center
San Diego, California, 92114, United States
University of Colorado Health Sciences Center
Aurora, Colorado, 80045, United States
Rocky Mountain Clinical Research, LLC
Golden, Colorado, 80401, United States
Gastroenterology of the Rockies
Lafayette, Colorado, 80026, United States
Arapahoe Gastroenterology Associates P.C.
Littleton, Colorado, 80120, United States
South Denver Gastroenterology
Lone Tree, Colorado, 80124, United States
Lynn Institute of Pueblo
Pueblo, Colorado, 81007, United States
Connecticut Gastroenterology Institute
Bristol, Connecticut, 06010, United States
Gastroenterology Center of Connecticut, P.C.
Hamden, Connecticut, 06518, United States
University of Florida
Gainesville, Florida, 32608, United States
University of Florida, Jacksonville
Jacksonville, Florida, 32209, United States
East Coast Institute for Research
Jacksonville, Florida, 32223, United States
Borland-Groover Clinic
Jacksonville, Florida, 32256, United States
Center for Advanced Gastroenterology
Maitland, Florida, 32751, United States
Osler Clinical Research
Melbourne, Florida, 32901, United States
University of Miami Miller School of Medicine
Miami, Florida, 33136, United States
United Medical Research Institute
New Smyrna Beach, Florida, 32168, United States
Compass Research LLC
Orlando, Florida, 32806, United States
Internal Medicine Specialists
Orlando, Florida, 32806, United States
University of South Florida
Tampa, Florida, 33606, United States
West Wind'r Research & Development, LLC
Tampa, Florida, 33607, United States
Shafran Gastroenterology Center
Winter Park, Florida, 32789, United States
Atlanta Gastroenterology Associates
Atlanta, Georgia, 30342, United States
Southeast Regional Research Group
Columbus, Georgia, 31904, United States
Atlanta Center for Gastroenterology, P.C.
Decatur, Georgia, 30033, United States
Gastroenterology Associates of Central Georgia
Macon, Georgia, 31201, United States
Digestive Research Associates
Newnan, Georgia, 30263, United States
St. Joseph's/Candler Health System
Savannah, Georgia, 31405, United States
DLW Research System
Snellville, Georgia, 30039, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
Carle Clinic Association P.C.
Urbana, Illinois, 58150, United States
Indianapolis Gastroenterology & Hepatology, Inc.- ARC
Indianapolis, Indiana, 46237, United States
Digestive & Liver Consultants
Clive, Iowa, 50325, United States
Iowa Digestive Disease Center
Clive, Iowa, 50325, United States
University Of Kansas
Kansas City, Kansas, 66160, United States
Cotton O'Neil Digestive Health Center
Topeka, Kansas, 66606, United States
University of Kentucky Medical Center
Lexington, Kentucky, 40536, United States
University Of Louisville
Louisville, Kentucky, 40202, United States
Gastroenterology Associates
Baton Rouge, Louisiana, 70809, United States
Metropolitan Gastroenterology Group, P.C.
Chevy Chase, Maryland, 20815, United States
Shah Associates
Prince Frederick, Maryland, 20678, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Boston Medical Center
Boston, Massachusetts, 02118, United States
The Center for Clinical Studies
Dearborn, Michigan, 48124, United States
Center for Digestive Health
Troy, Michigan, 48098, United States
Gastroenterology Associates of Western Michigan, P.L.C.
Wyoming, Michigan, 49519, United States
Minnesota Gastroenterology, P.A.
Plymouth, Minnesota, 55486, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
Digestive Health Specialists
Tupelo, Mississippi, 38801, United States
Truman Medical Center
Kansas City, Missouri, 64108, United States
Center for Digestive and Liver Diseases, Inc.
Mexico, Missouri, 65265, United States
Washington University
St Louis, Missouri, 63110, United States
St. Louis Center for Clinical Research
St Louis, Missouri, 63128, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
Affiliates in Gastroenterology PA
Morristown, New Jersey, 07960, United States
University of Medicine and Dentistry of New Jersey-NJMS
New Brunswick, New Jersey, 08903, United States
The Gastroenterology Group of South Jersey
Vineland, New Jersey, 08360, United States
Hepatobiliary Associates of New York
Bayside, New York, 11358, United States
Digestive Health Physician
Cheektowaga, New York, 14225, United States
Long Island Clinical Research Associates
Great Neck, New York, 11021, United States
Long Island Gastroenterology Group, P.C.
Merrick, New York, 11566, United States
New York Presbyterian Hospital
New York, New York, 10021, United States
Present Chapman Marion Steinlauf MD PC
New York, New York, 10028, United States
Kim, Chung MD (Private Practice)
Pittsford, New York, 14534, United States
University of Rochester
Rochester, New York, 14642, United States
Long Island Digestive Disease Consultants
Setauket, New York, 11733, United States
SUNY Stony Brook University Medical Center
Stony Brook, New York, 11794, United States
Syracuse Gastroenterological Associates
Syracuse, New York, 13210, United States
Asheville Gastroenterology Associates, P.A.
Asheville, North Carolina, 28801, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Charlotte Gastroentology and Hepatology, P.L.L.C
Charlotte, North Carolina, 28207, United States
Northwest Piedmont Clinical Research, Inc.
Elkin, North Carolina, 28621, United States
Burke Research Associates
Morganton, North Carolina, 28655, United States
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, 27157, United States
Consultants for Clinical Research Inc.
Cincinnati, Ohio, 45219, United States
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
Dayton Science Institute
Dayton, Ohio, 45415, United States
Options Health Research
Tulsa, Oklahoma, 74104, United States
The Oregon Clinic-West Hills Gastroenterology
Portland, Oregon, 97225, United States
University of Pittsburgh Medical Center - Cancer Centers
Pittsburgh, Pennsylvania, 15213, United States
Medical University Of SC CAR
Charleston, South Carolina, 29425, United States
Consultants in Gastroenterology
Columbia, South Carolina, 29203, United States
Gastroenterology Center of the MidSouth, PC
Germantown, Tennessee, 38138, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Austin Gastroenterology, PA
Austin, Texas, 78705, United States
Bayou City Research, Ltd.
Houston, Texas, 77024, United States
Gastroenterology Consultants
Houston, Texas, 77034, United States
Jacon Medical Research Associates
Houston, Texas, 77090, United States
Digestive Health Center
Pasadena, Texas, 77504, United States
Alamo Medical Research
San Antonio, Texas, 78215, United States
Gastroenterology Clinic of San Antonio
San Antonio, Texas, 78229, United States
Stone Oak Research Foundation
San Antonio, Texas, 78258, United States
Digestive Health Specialists of Tyler
Tyler, Texas, 75701, United States
Granite Peaks Gastroenterology
Sandy City, Utah, 84094, United States
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
Gastroenterology Associates of Northern Virginia
Fairfax, Virginia, 22031, United States
Digestive and Liver Disease Specialist Ltd.
Norfolk, Virginia, 23502, United States
Hunter Holmes McGuire VA Medical Center
Richmond, Virginia, 23249, United States
Northwest Gastroenterology Associates
Bellevue, Washington, 98004, United States
Puget Sound Medical Research
Edmonds, Washington, 98026, United States
Pharmaseek, LLC
Madison, Wisconsin, 53717, United States
Wisconsin Center for Advanced Research
Milwaukee, Wisconsin, 53215, United States
Medical College Of Wisconsin
Milwaukee, Wisconsin, 53226, United States
GI Research
Edmonton, Alberta, T5H4B9, Canada
Zeidler Ledcor Center-Univerisity of Alberta
Edmonton, Alberta, T6G2X8, Canada
Royal University Hospital
Saskatoon, Saskatchewan, S7N 0W8, Canada
Pharmaseek, LLC
Ponce, 716, Puerto Rico
Related Publications (9)
Wyant T, Yang L, Rosario M. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials. AAPS J. 2020 Nov 16;23(1):3. doi: 10.1208/s12248-020-00518-0.
PMID: 33200296DERIVEDOkamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intest Res. 2021 Jan;19(1):95-105. doi: 10.5217/ir.2019.09167. Epub 2020 Jul 10.
PMID: 32635680DERIVEDSands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T. Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3. Inflamm Bowel Dis. 2019 Jul 17;25(8):1375-1382. doi: 10.1093/ibd/izy384.
PMID: 30615117DERIVEDFeagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 1;13(1):50-57. doi: 10.1093/ecco-jcc/jjy125.
PMID: 30203005DERIVEDFeagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, Colombel JF. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Jan;17(1):130-138.e7. doi: 10.1016/j.cgh.2018.05.026. Epub 2018 May 29.
PMID: 29857145DERIVEDFeagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27;12(5):621-626. doi: 10.1093/ecco-jcc/jjy019.
PMID: 29471381DERIVEDColombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18.
PMID: 26893500DERIVEDRosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn WJ, Feagan BG, Reinisch W, Fox I. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015 Jul;42(2):188-202. doi: 10.1111/apt.13243. Epub 2015 May 20.
PMID: 25996351DERIVEDSandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.
PMID: 23964933DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Medical Director
- Organization
- Millennium Pharmaceuticals Inc
Study Officials
- STUDY DIRECTOR
Medical Monitor
Millennium Pharmaceuticals, Inc.
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- FACTORIAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 31, 2008
First Posted
November 3, 2008
Study Start
December 1, 2008
Primary Completion
March 1, 2012
Study Completion
May 1, 2012
Last Updated
July 21, 2014
Results First Posted
July 21, 2014
Record last verified: 2014-06